Treatment for Anasarca Related to Protein-Losing Enteropathy
Dietary Management
- A diet low in long-chain triglycerides (<5% of total energy intake) and enriched with medium-chain triglycerides (>20% of total energy intake) is recommended for protein-losing enteropathy, particularly for intestinal lymphangiectasia 1
- Energy and protein intakes should be at least 30 kcal/kg actual body weight/day and 1.2 g/kg actual body weight/day to address malnutrition 1
- A protein-energy enriched diet should be provided due to frequent malnutrition in these patients 1
Cardiac-Related Protein-Losing Enteropathy
- Heart transplantation may be beneficial for severe systemic ventricular dysfunction or protein-losing enteropathy in patients with Fontan circulation 2, 3
- Creation of an atrial septal fenestration or Fontan conversion should be considered for protein-losing enteropathy not amenable to medical therapy in Fontan patients 2, 3
- Pulmonary vasoactive medications can improve exercise capacity in adults with Fontan repair and may help manage symptoms of protein-losing enteropathy 3, 4
Pharmacological Management
- Corticosteroids, specifically budesonide, may be helpful for patients with hypoalbuminemia in the setting of protein-losing enteropathy poorly responsive to other therapies 3, 4
- Budesonide has fewer systemic effects than other oral steroids, but close monitoring for signs of hypercortisolism remains necessary 3, 4
- Aldosterone antagonists or subcutaneous unfractionated heparin may stabilize the proteoglycan layer of the gut in Fontan-related protein-losing enteropathy 3, 4
Management Based on Specific Etiologies
- For inflammatory bowel disease-related protein-losing enteropathy, immunosuppressive therapy targeting the underlying inflammation is indicated 5, 6
- For infectious causes, appropriate antimicrobial therapy should be initiated 5, 6
- For medication-induced enteropathy, discontinuation of the offending agent is recommended 5, 6
- For constrictive pericarditis, surgical pericardiectomy is the definitive treatment 5, 6
Monitoring and Follow-up
- Regular monitoring of serum albumin levels is essential to evaluate treatment efficacy 5, 7
- Repeat endoscopy with biopsies may be necessary to assess response to therapy, typically after 12 months of treatment 5
- For cardiac causes, regular cardiac evaluation with echocardiography, electrocardiogram, and other cardiac testing is recommended 3, 4